Phenoxodiol inhibits growth of metastatic prostate cancer cells

Prostate

Volumn 70, Issue 11, 2010, Pages 1211-1221

  Aguero, Martin F ^a   Venero, Marina ^a   Brown, David M ^b   Smulson, Mark E ^a   Espinoza, Luis A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Marshal Edwards Inc   (Australia)

Author keywords

Clonogenecity; DU145 cells; LNCaP cells PC3 cells; Poly(ADP ribose) polymerase 1 (PARP 1)

Indexed keywords

ANTINEOPLASTIC AGENT; PHENOXODIOL; UNCLASSIFIED DRUG; ISOFLAVONE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CELL MEMBRANE; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; BAGG ALBINO MOUSE; CELL GROWTH; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; MALE; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; HUMANS; ISOFLAVONES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955935798     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21156     Document Type: Article

References (36)

1. Lopez-Lazaro M. Flavonoids as anticancer agents: Structure-activity relationship study. Curr Med Chem Anticancer Agents 2002;2(6):691-714. (Pubitemid 35175268)
2. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003;47(2):111-117.
3. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest 2003;21(5):744-757.
4. Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 1998;31(3):184-191. (Pubitemid 28481852)
5. Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, Jovanovic BD, Shapiro A, Hernandez L, Goetz A, Llorens V, Lieberman R, Crowell JA, Poisson BA, Bergan RC. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003;12(11 Pt 1):1213-1221.
6. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Jeffcoat RA, Crowell J, Paglieri J, Zeisel SH. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003;77(4):875-882.
7. Kelly GE, Husband AJ. Flavonoid compounds in the prevention and treatment of prostate cancer. Methods Mol Med 2003;81:377-394.
8. de Souza PL, Liauw W, Links M, Pirabhahar S, Kelly G, Howes LG. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemother Pharmacol 2006;58(4):427-433. (Pubitemid 43999790)
9. Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 2005;65(8):3364-3373.
10. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003;22(17):2611-2620.
11. Yu F, Watts RN, Zhang XD, Borrow JM, Hersey P. Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells. Anticancer Drugs 2006;17(10):1151-1161.
12. Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res 1999;59(7):1606-1614. (Pubitemid 29160133)
13. Kimura K, Gelmann EP. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem 2000;275(12):8610-8617.
14. Alvero AB, Brown D, Montagna M, Matthews M, Mor G. Phenoxodiol-topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. Cancer Biol Ther 2007;6(4):
15. Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D, Vadas MA. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 2006;118(10):2412-2420.
16. Jacobson EL, Lange RA, Jacobson MK. Pyridine nucleotide synthesis in 3T3 cells. J Cell Physiol 1979;99(3):417-425.
17. Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005;12(1):73-80.
18. Oki T, Sowa Y, Hirose T, Takagaki N, Horinaka M, Nakanishi R, Yasuda C, Yoshida T, Kanazawa M, Satomi Y, Nishino H, Miki T, Sakai T. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. FEBS Lett 2004;577(1-2):55-59.
19. Barre B, Vigneron A, Coqueret O. The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter. J Biol Chem 2005;280(16):15673-15681. (Pubitemid 40616686)
20. Gonzalez T, Seoane M, Caamano P, Vinuela J, Dominguez F, Zalvide J. Inhibition of Cdk4 activity enhances translation of p27kip1 in quiescent Rb-negative cells. J Biol Chem 2003;278(15):12688-12695.
21. Espinoza LA, Crotti LB. Roles of PARP-1 and p53 in the maintenance of genome integrity. Hauppauge, NY: Nova Science Publishers; 2007. pp 35-50.
22. Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Samara R, Espinoza LA, Hassa PO, Hottiger MO, Smulson ME. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase. Oncogene 2003;22(52):8460-8471.
23. Espinoza LA, Tenzin F, Cecchi AO, Chen Z, Witten ML, Smulson ME. Expression of JP-8-induced inflammatory genes in AEII cells is mediated by NF-kappaB and PARP-1. Am J Respir Cell Mol Biol 2006;35(4):479-487.
24. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005;65(14):6282-6293.
25. Kulik G, Carson JP, Vomastek T, Overman K, Gooch BD, Srinivasula S, Alnemri E, Nunez G, Weber MJ. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. Cancer Res 2001;61(6):2713-2719.
26. Brown DM, Heaton A, Husband AJ. Idronoxil. Drugs Future 2008;33(10):844-860.
27. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T, Mor G. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006;106(3):599-608. (Pubitemid 43157623)
28. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
29. Silasi DA, Alvero AB, Rutherford TJ, Brown D, Mor G. Phenoxodiol: Pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother 2009;10(6):1059-1067.
30. Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol 2006;17(5):860-865.
31. Constantinou AI, Husband A. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4- hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 2002;22(5):2581-2585.
32. Nguewa PA, Fuertes MA, Alonso C, Perez JM. Pharmacological modulation of poly(ADP-ribose) polymerase-mediated cell death: Exploitation in cancer chemotherapy. Mol Pharmacol 2003;64(5):1007-1014.
33. Chiarugi A, Moskowitz MA. Cell biology. PARP-1 - A perpetrator of apoptotic cell death? Science 2002;297(5579):200-201.
34. McPherson RA, Galettis PT, de Souza PL. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. Br J Cancer 2009;100(4):649-655.
35. Mor G, Fu HH, Alvero AB. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Invest Drugs 2006;7(6):542-548. (Pubitemid 43891033)
36. Davies RJ, Frydenberg M, Tulloch A. Phase I/II safety, tolerability and efficacy study of oral phenoxodiol in patients with hormone-refractory prostate cancer (HRPC). Br J Urol 2009, unpublished results.